Ernexa Therapeutics (formerly Eterna Therapeutics) — Cyborg Score 3/10

Strategic Profile

Ernexa is developing two preclinical-stage cell therapy products: ERNA-101, designed to activate immune response against cancer cells, and ERNA-102, designed to target inflammation in autoimmune disease. The company is focused on advancing ERNA-101 for triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer.

Cyborg Score Rationale

ERNA's volatility increased from 16% to 21% over the past year, and the company holds several negative signals with weak expected performance. As a preclinical-stage biotech with minimal revenue and negative cash flow, execution risk on clinical trials is extremely high.

Top Insights

• Recent name change (March 2025) signals strategic pivot to focus on specific cancer and autoimmune indications rather than platform approach
• Company regained NASDAQ compliance in November 2024, resolving prior listing concerns
• Preclinical-stage means no clinical data yet and years before potential revenue
• High volatility (21% weekly) reflects low liquidity and speculative investor base typical of micro-cap biotech

Named Competitors

• CAR-T Cell Therapy — Approved genetically modified T-cell immunotherapies for blood cancers
• Cell Therapy Platform — Developing cell therapies for blood cancers and solid tumors
• Mesenchymal Stem Cell Therapies — Engineering cell therapies with focus on immune modulation

Recent Developments

• (December 2025) Presented data at ASH Annual Meeting on cell therapy programs
• (May 2025) Established Texas subsidiary to support ERNA-101 development and clinical operations
• (March 2025) Completed name change to Ernexa Therapeutics reflecting strategic refocus
• (November 2024) Regained NASDAQ compliance for continued listing

Open the full interactive Ernexa Therapeutics (formerly Eterna Therapeutics) report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.